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Summary Monoclonal antibodies against two epitopes of FGFR-1 have been used to investigate FGFR-1 expression in the normal and
neoplastic human breast. Different forms are detected in the different cell types constituting the normal breast. Moreover, breast cancer cells
lack one form of FGFR-1. Western blot analysis showed 115-kDa and 106-kDa forms of FGFR-1 within the human breast. The 115-kDa band
corresponds to the beta form of FGFR-1, whereas the 106-kDa band is truncated at the carboxyl terminus. The 106-kDa form of FGFR-1 is
the major form present in breast fibroblasts and myoepithelial cells, whereas epithelial cells contain equal amounts of the 115-kDa and 106-
kDa forms. Breast cancer cells, however, appear to contain only the 115-kDa form of FGFR-1. This expression pattern is reflected in
malignant and non-malignant tissue samples. Using reverse transcription polymerase chain reaction (RT-PCR) analysis, we have shown that
the 106-kDa FGFR-1 isoform is not the previously described alpha 2 receptor that arises from a 25-base pair insertion in the second kinase
domain. It is probable that the 106-kDa FGFR-1 has different signalling properties to the full-length receptor, having lost at least one tyrosine
at amino acid 766, which is required forphospholipase C activation. This form of FGFR-1 appears to be lost in all breast cancercells analysed
and its absence may have a bearing on malignancy.
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The family offibroblast growth factors comprises nine structurally
related polypeptides that are mitogenic for a variety of cells and
that are involved in embryogenesis, angiogenesis and differentia-
tion (Burgess and Maciag, 1989; Miyamoto et al, 1993). Their
cellular response is thought to be mediated through cell surface
receptors that belong to the superfamily oftyrosine kinase recep-
tors (Johnson et al, 1991; Keegan et al, 1991; Partanen et al, 1991;
Jaye et al, 1992). Extracellular matrix and cell surface heparan
sulphate proteoglycans are involved in the interaction of these
growth factors with their receptors (Klagsbrun and Baird, 1991;
Kan et al, 1993).
The four fibroblast growth factor receptors are type four tyro-
sine kinase receptors and are encoded by four distinct genes. They
consist of an extracellular ligand binding domain, a transmem-
brane part and an intracellular split kinase domain that is involved
in signal transduction (Figure lA). They share a high amino acid
sequence homology and are characterized by a large number of
variant forms generated by alternative mRNA splicing (Hou et al,
1991; Jaye et al, 1992). Variants include: the full-length alpha
form; the beta form lacking the first immunoglobulin domain; the
intracellular gamma form lacking a signal peptide, the first
immunoglobulin domain and the acidic box; and a truncated form,
alpha 2, which results from a 25-bp insertion in the second kinase
domain leading to aframe shift (Figure IB). Theprecisebiological
function ofthese variant forms is not yet known, but it is believed
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that they play an important role in receptor activation by affecting
ligandrecognition andbinding affinity (Miki et al, 1992; Werneret
al, 1992; Shi et al, 1993; Hanneken et al, 1994). Truncated forms
of FGFR-1 and FGFR-3, lacking tyrosine kinase activity, can act
as dominant negative receptors and have been shown to abolish
the function of not only FGFR-1 but also FGFR-2 and FGFR-3
(Ueno et al, 1992; Johnston et al, 1995).
FGFR-1 is the product of the flg gene, which consists of 19
exons and binds both FGF1 and FGF2 as well as FGF4, FGF5,
FGF6 (bound by FGFR-lIIIIb) and FGF3 (bound by FGFR-lIIIc)
(Jaye et al, 1992; Ornitz et al, 1996). It is widely distributed in a
variety of human tissues, including breast (Hughes and Hall,
1993). As a signal-transducing protein, changes in the level or
isoform expression of FGFR-1 may contribute to tumorigenesis.
Thefig gene has been shown to be amplified in 12.7% of human
breast cancers (Adnane et al, 1991) and, in a recent series, gene
amplification was found in 22% of the tumours studied (Penault-
Llorca et al, 1995). The beta form of FGFR-1 seems to be the
predominant form in both normal and malignant breast tissues and
cell lines as shown by RT-PCR (Luqmani et al, 1995; Penault-
Llorca et al, 1995). The ratio of the beta to the alpha isoform is
higher in malignant breast tissues and a high ratio is associated
with a reduced disease-free survival in patients with breast cancer
(Luqmani et al, 1995). FGFR-1 has also been linked with malig-
nant progression ofhuman astrocytomas, and a shift in expression
from the alpha form to the beta form of FGFR-1 has been seen in
intermediate grades of astrocytomas as they progressed from
benign to malignant phenotype (Yamaguchi et al, 1994). Finally,
Becker et al (1992) demonstrated that inhibition of the FGFR-1
gene in malignant melanomas led to inhibition ofproliferation and
also signs ofdifferentiation (Becker et al, 1992).
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We have investigated the expression of FGFR-1 and its variant
forms in mammary cell lines, malignant and normal breast tissues
and purified populations ofepithelial cells, myoepithelial cells and
fibroblasts from normal breast. We have found that the 115-kDa
beta form ofFGFR-1 is the predominantisoformexpressed in both
benign and malignant epithelial cells. However, a second 106-kDa
form ofFGFR-1 is expressed in breast fibroblasts and myoepithe-
lial cells. Interestingly, although normal and benign epithelial cells
contained the 106-kDa FGFR-1, expression of this form was lost
in malignant epithelial cells.
MATERIALS AND METHODS
Materials
Nitrocellulose membranes were from Sartorius, polyacrylamide
solution (Protogel) from National Diagnostics, agarose gel from
Boehringer (Mannheim, Germany), enhanced chemiluminescence
(ECI) reagents from Amersham (UK), RNAzol from Biogenesis
(Bournemouth, UK), reverse transcriptase from Gibco-BRL
(Paisley, UK), Taq polymerase from Peninsula Laboratories (UK)
and dNTPs from Pharmacia (Uppsala, Sweden). All otherreagents
were obtained from Sigma Chemicals (Poole, UK), unless other-
wise indicated.
Antibodies
Two anti-FGFR- 1 monoclonal antibodies were used: the first one
was raised against amino acids pro22-his325 of the beta form of
FGFR-1 and recognizes both the alpha and beta forms of the
receptor and was used for Western blotting (Upstate
Biotechnology Incorporated, USA); the second antibody was
against a peptide corresponding to the COOH terminus,
Leu807-Arg822, of FGFR-1. The peptide was prepared on a Wang
resin using the AMS 422 Multiple Peptide Synthesizer by the
Fmoc method, and its purity was checked by reverse-phase HPLC.
Ten milligrams of the peptide was coupled to 10 mg of purified
protein derivative (Morrison et al, 1987), and this conjugate was
used to inject female Balb/c mice. The splenocytes of one of the
mice were fused with Sp2/0 myeloma cells and, after 7 days, the
hybridoma supernatants were screened by ELISA. Supernatants
from strongly reacting hybridomas were then tested by Western
blotting and on cryostat sections of breast tissues to identify the
most suitable hybridoma forrecloning. This antibody was used for
immunohistochemistry and Western blotting.
A further polyclonal antibody against a 26-amino-acid peptide
(DALPSAEDDDDEDDSSSEEKEADNTK) from the extracel-
lular domain (residues 119-144) of chicken FGFR-1 (Upstate
Biotechnology, USA) was used for immunohistochemistry.
Antibodies to detect FGFR-2, FGFR-3 and FGFR-4 were poly-
clonal antisera from Santa Cruz Biotechnology.
Cell lines
Eight human mammary cell lines were used in this study: three
cell lines derived from normal breast tissue - HBL-100 (myo-
epithelial), HBR SV 1.6.1 (epithelial) and MCF-lOa (epithelial) -
and five malignant breast cell lines - MDA-MB-231, MCF-7,
T47D, ZR-75-1 and SKBr 3. All but two of these cell lines were
cultured in RPMI 1640 medium buffered with 25 mm Hepes and
supplemented with 10% fetal calf serum, 100 units ml-1 penicillin,
100gg ml1 streptomycin and 2 mm L-glutamine. Monkey kidney
(Cos-1) cells were also cultured in the same medium. The SKBr 3
cells were grown in McCoy's 5A medium with the same supple-
ments and the MCF-lOa cells in a medium containing equal quan-
tities of Dulbecco's modified Eagle medium and Ham's nutrient
mixture F-12 buffered with 15 mM Hepes with the following
supplements: 5% horse serum, 2 mm L-glutamine, 100 units ml-1
penicillin, 100 ,ug ml-' streptomycin, 10 ,ug ml insulin, 1.4 nm
hydrocortisone, 100 ng ml- cholera enterotoxin and 20 ng ml'
epidermal growth factor. Cells were harvested at about 80%
confluence for both protein analysis and RNA extraction.
Tissues and purified populations of normal breast cells
Breast tissues obtained at surgery were snap frozen and stored in
liquid nitrogen. We collected tissue samples from nine cancers,
five fibroadenomas, five reduction mammoplasties (normal breast
tissue) and three cases of fibrocystic disease. Frozen sections of
these were stained with haematoxylin and eosin to confirm the
histological diagnosis. Separated breast fibroblasts, epithelial and
myoepithelial cells were prepared from reduction mammoplasty
specimens by immunomagnetic separation using the methods of
Stampfer et al (1980) and Gomm et al (1995).
Transient transfections
Ten million subconfluent Cos-1 cells were trypsinized, washed in
medium and then in HeBs buffer (20 mm HEPES pH 7.0, 140 mm
sodium chloride, 5 mm potassium chloride and 6 mm dextrose)
and finally resuspended in 0.5 ml of HeBs buffer. Thirty micro-
grams of pSG5-FGFR and 100jig ofhuman placental DNA were
added to the suspension ofCos-1 cells (Green etal, 1988). Plasmid
DNA was omitted from the control transfection. The cells were
then electroporated at 500 ,uFd and 0.2 V using a Biorad Gene
Pulser and placed in 90-mm dishes. In this system, FGFR is maxi-
mally expressed 48-72 h after electroporation, and the cells were
therefore harvested during this period.
SDS-PAGE and Western blotting
Monolayers of cultured cells grown in Petri dishes were lysed in
standard SDS-PAGE sample buffer (100 mm Tris-HCl pH 6.8,
10% glycerol, 1% sodium dodecyl sulphate (SDS), 10% 2-
mercaptoethanol, 0.002% bromophenol blue). Frozen tissues were
diced into very small pieces and thawed in phosphate-buffered
saline (PBS) containing 1% NP40, 0.1% SDS, 100jg ml-' phenyl-
methylsulphonyl fluoride (PMSF) and 5 mg ml-1 aprotinin. The
tissues were further disrupted and homogenized with a Polytron
device (Kinematica AG) and centrifuged at 14 000g for 20 min at
4°C. The supernatant was then mixed with an equal volume of
SDS-PAGE sample buffer (as above). The protein content of the
samples was measured using the Bradford method (Bradford,
1976), and 40jg of protein were run through a 7.5% polyacryl-
amide gel using a mini-gel apparatus (Hoefer). The separated
proteins were transferred onto nitrocellulose membranes by
overnight blotting at 4°C and blocked with 3% milk powder in
PBS with 0.1% Tween 20 (PBS-T) for 1 h at room temperature.
The blots were then probed with one of the anti-FGFR-1 anti-
bodies for 1 h, followed by an incubation with an anti-mouse IgG
horseradish peroxidase conjugate for 1 h. After five washes
with PBS-T, bands were visualized using the ECL method. All
British Journal ofCancer (1997) 76(11), 1419-1427 0 CancerResearch Campaign 1997FGFR-1 variants in human breast 1421
TK KI TK CT
U.
tC 1X% IIr,IS .66%
.117/150
11 %~
~ ~ :7
* V %
-rISkD0t
'-1*ICs
o ';,'' '' . . ' . . , . 1201II
Figure 1 Description of monoclonal antibodies against FGFR-1 and variant forms of FGFR 1. (A) Structure of FGFR-1 and position of peptides to which the
monoclonal antibodies bind. 1, 11 and IlIl refer to immunoglobulin domains, TM to the transmembrane domain, JM to the juxtamembrane domain, TK to the
tyrosine kinase domain, KI to the kinase insert domain and CT to the carboxyl terminal tail. (B) Diagrammatic representation of the al, j31 and a2 forms of
FGFR-1
antibodies were removed from the membranes in acidic conditions
using 0.1 M glycine pH 2.5 and then re-probed with the other anti-
FGFR-1 antibody using the protocol described above. These
experiments were repeated using the anti-FGFR-1 antibodies in
reverse order.
FGFR-2, FGFR-3 and FGFR-4 were detected in transfected cos-
1 cells by running 50 jg ofprotein from cell lysates on 7.5% poly-
acrylamide gels and transferring to a nitrocellulose membrane as
described above. The membranes were blocked with 3% milk
powder in PBS with 0.1% Tween 20 (PBS-T) for 1 h at room
temperature. The blots were then probed with purified rabbit anti-
sera against FGFR-2, FGFR-3 or FGFR-4 (Santa Cruz) for 1 h,
followed by an incubation with an anti-rabbit IgG horseradish
peroxidase conjugate for 1 h. After five washes with PBS-T, bands
were visualized using the ECL method.
RNA extraction, reverse transcription and PCR
amplification
RNA was extracted from cultured cell lines using the modified
RNAzol procedure (Chomczynski and Saachi, 1987). In the case
ofseparated cells fromreduction mammoplasty tissue, mRNA was
extracted from 2.5 million epithelial or myoepithelial cells using
the Dynabead mRNA direct protocol (Dynal). Reverse transcrip-
tion was performed as described previously (Luqmani et al, 1992),
using 2 jig ofRNA and 500 ng ofthe random primerpdN6.
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Figure 2 Western blots showing that the monoclonal antibodies bind to
FGFR-1 but not to other classes of FGFR. Cos-1 cells were transiently
transfected with FGFR-1, -2, -3 or -4 cDNAs. Lysates from these
transfections were run on a 7.5% polyacrylamide gel and transferred to
nitrocellulose. Blots were probed with: (A) the antibody against the ligand
binding domain and (B) the antibody against the carboxyl terminus of FGFR-
1. Lanes 1, 2, 3 and 4 correspond to FGFR-1, -2, -3 and -4 respectively.
Section C is probed with antibodies against FGFR-2 (lanes 1 and 2), FGFR-3
(lanes 3 and 4) and FGFR-4 (lanes 5 and 6). Lanes 1, 3 and 5 contain
untransfected cos-1 cells, whereas lane 2 contains cos-1 cells transfected
with FGFR-2, lane 4 contains cells transfected with FGFR-3 and lane 6
contains cells transfected with FGFR-4
In order to look for an insertion of25 bases in the kinase coding
region of FGFR-1, cDNA was amplified by using 1 unit of Taq
polymerase, 100 ng of each of the primers [5'-CCCCAGGGCTG-
GAATACTGC-3' (sense) and 5'-CGAGGCCAAAGTCTGC-
TATC-3' (antisense)] in a total volume of 50gl. Forty sequential
cycles of denaturation at 95°C for 1 min, annealing at 50°C for
1 min and extension at 72°C for 30 s extended to 10 min for the
final cycle were used to amplify FGFR-1 cDNA. Ten microlitres of
the PCR products were run on 4% agarose gels containing ethidium
bromide, and bands were visualized with ultraviolet light.
Semiquantitative RT-PCR to investigate expression levels of
FGFR1 was carried out using a method described previously
(Luqmani et al, 1992). cDNA was amplified using 1 unit of Taq
polymerase in 100 ,ul containing 200 ng of the primers 5'-CCTCT-
TCTGGGCTGTGCT-3' and 5'-TCl 1 CTGGGGATGTCC-3' for
FGFR-1 cDNA and primers 5'-CATCTCTTGCTCGAAGA-
AGTCCA-3' and 5'-ATCATGTl 7GAGACCTTCAA-3' for actin.
The reaction consisted of sequential cycles of denaturation at 94°C
for 1 min, annealing at 45°C for 1 min and extension at 72°C for
1 min (extended to Omin for the final cycle). An aliquot was
removed after 18 cycles forestimation ofactin product, and the reac-
tion was continued for a further ten cycles forestimation ofFGFR-1.
Aliquots (10gl) of the 28- and 18-cycle PCR products were run on
separate 1% agarose gels and alkali blotted overnight onto Hybond
Figure 3 Western blot analysis of FGFR-1 expression in breast cell lines
and purified cell populations from normal breast. Lysates of breast cell lines
and purified cell populations from normal breast were run on a 7.5%
polyacrylamide gel and transferred to nitrocellulose. Blots were probed with
the two antibodies against FGFR-1: (A) Antibody against the carboxyl
terminus and (B) antibody against the ligand-binding domain. Lane 1, purified
-205 kDa myoepithelial cells; lane 2, purified epithelial cells; lane 3, normal breast
fibroblasts; lane 4, HBL-100 non-malignant myoepithelial cells; lane 5, MCF-
1OA non-malignant epithelial cells; lane 6, HBR-SV 161 non-malignant
epithelial cells; lane 7, MDA-MB-231 breast cancer cells; lane 8, MCF-7
breast cancer cells; lane 9, T47D breast cancer cells; lane 10, ZR-75-1 breast
cancer cells
N+ membrane. Hybridization was carried out as describedby Church
and Gilbert (1984). A phosphoimager was used to quantify the inten-
sity ofeach band. The value forFGFR-1 was nonnalized by dividing
the signal forFGFR-1 with that for actin.
Immunohistochemistry
Cryostat sections of breast tissue were prepared and fixed in 4%
formaldehyde. Sections were stained as described previously
(Gomm et al, 1991). They were blocked with 10% goat serum in
PBS for 30 min and then incubated overnight at 4°C with each of
the two anti-FGFR-l monoclonal antibodies (0.5 jg ml-') and the
anti-FGFR-1 polyclonal (1 jg ml') and the controls with mouse
IgG (0.5 jg ml-') or rabbit IgG (1 gg ml-'). After washing with
PBS, sections were incubated with biotinylated anti-mouse IgG or
biotinylated anti-rabbit IgG in the case ofthe polyclonal, followed
by an avidin-biotin peroxidase complex. After further extensive
washes in PBS, staining was visualized with 0.05% 3,3'-diamino-
benzidine and counterstained with Gill's haematoxylin.
RESULTS
Characterization of anti-FGFR-1 antibodies
The four FGFRs share considerable sequence homology and
certain regions are highly conserved. Monoclonal antibodies
against two receptorepitopes were used in this study. The first was
against the ligand-binding domain of FGFR-1 (63-81% homolo-
gous to other FGF receptors) and the second against the carboxyl
terminus (38-60% homologous to other FGF receptors) (Figure
IA). It was therefore important to test the specificity of the two
anti-FGFR-1 antibodies and exclude cross-reactivity with the
other three FGFRs. In order to do this, Cos-I cells were trans-
fected with full-length FGFR 1-4 cDNA under an SV40 promoter.
Expression of the transfected receptors was checked by Western
blotting using previously characterized antibodies against each
receptor (Johnston et al, 1995). All four receptors were expressed
as expected (results not shown). Subsequent Western blotting
experiments used the two monoclonal antibodies against FGFR-I
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Figure 4 Western blot analysis of FGFR-1 expression in normal, benign
and malignant breast tissue samples. Lysates of tissue homogenates were
run on a 7.5% polyacrylamide gel and transferred to nitrocellulose. Blots were
probed with the antibody against the ligand-binding domain of FGFR-1.
Examples of these blots are shown: (A) Lanes 1, 3 and 5, benign fibrocystic
disease; lanes 2 and 4, normal breast tissue; lanes 6-10 fibroadenomata. (B)
Lanes 1-5, breast cancers
to probe the filters. As seen in Figure 2, both antibodies recognized
a band of 135-kDa corresponding to the expected size of full-
length FGFR-l but did not bind to the other three receptors,
showing that they are specific for FGFR-1.
Expression of FGFR-1 in mammary cell lines and
separated populations of epithelial and myoepithelial
breast cells
Western blot analysis was used to detect FGFR-1 expression in
breast cell lines and separated epithelial and myoepithelial cells
and fibroblasts from reduction mammoplasty tissue. An immuno-
reactive band of 115 kDa was seen with both antibodies in all
mammary cell lines tested. The level of expression in malignant
and non-malignant cells tended to be similar, but the highest
expressing samples tended to be malignant (Figure 3A and B).
When the blots were probed with the antibody against the ligand
binding domain ofFGFR-1, a second band of 106 kDa was visual-
ized in the three benign cell lines (Figure 3B). In the HBL-100 cell
line (myoepithelial phenotype), the intensity of this band was
stronger than that of the band associated with the 115-kDa beta
form, indicating that this is the predominant form of FGFR-1
expressed. However, in the HBR-SV-1.6.1 and MCFlOa cell lines
(non-malignant epithelial cells), both bands were of equal inten-
sity. Both monoclonal antibodies produced clean blots, with no
other bands appearing after short exposure times.
The expression pattern in purified populations of fibroblasts,
epithelial and myoepithelial cells was very similar to that of the
cell lines. The epithelial cells expressed both the 106- and 115-kDa
forms in about equal amounts, whereas the myoepithelial cells and
the fibroblasts expressed predominantly the former. As the 106-
kDa product is not recognized by the antibody against the COOH
Figure 5 Immunocytochemical staining of normal and malignant human
breast frozen sections using antibodies against the C-terminal tail and
extracellular domain of FGFR-1. (A) A frozen section of normal human breast
stained with 0.5 ug ml-' antibody to the C-terminal tail of FGFR-1. (B) A
frozen section of normal human breast stained with 0.5 gg ml-' mouse IgG.
(C) A frozen section of invasive breast cancer stained with 0.5 jg ml-'
antibody to the C-terminal tail of FGFR-1. (D) A frozen section of invasive
breast cancer stained with 0.5 gg ml-' mouse IgG. (E) A frozen section of
normal human breast stained with 1 gg ml-' antibody to the extracellular
region of FGFR-1. (F) A frozen section of normal human breast stained with
1 gg ml-' mouse IgG. (G) A frozen section of invasive breast cancer stained
with 1 igg ml-' antibody to the extracellular region of FGFR-1. (H) A frozen
section of invasive breast cancer stained with 1 gg ml-1 mouse IgG.
Magnification x 200
terminus of the molecule, it probably represents a C-terminally
truncated form ofthe receptor.
The 135-kDa alpha form ofFGFR-1 was undetectable in all cell
lines tested and in the separated populations offibroblasts, epithe-
lial and myoepithelial cells.
Expression of FGFR-1 in human breast tissues
Lysates from all 22 breast tissues were separated on SDS-poly-
acrylamide gel and probed with both anti-FGFR-1 antibodies.
Examples ofthese Western blots probed with the antibody against
British Joumal of Cancer (1997) 76(11), 1419-1427
A
106 kDa--
B
106 kDa---O
0CancerResearch Campaign 19971424 C Yiangou etal
A
FGRF-1 I
Actin
1 2 3 4- 5 7
Figure 6 Expression of FGFR-1 mRNA in purified populations of breast
cells. RT-PCR was used to amplify FGFR-1 and actin message from breast
cells. Products were run on agarose gels. Bands were visualized by
Southern blotting and a phosphoimager was used to quantify expression.
The figure shows phosphoimager analysis of a representative experiment:
lane 1, myoepithelial cells; lanes 2-4 epithelial cells; lane 5, HBL-100
myoepithelial cell line; lane 6, MCF7 breast cancer cell line; lane 7, breast
fibroblasts
TM JM TK KI TK CT
25-bp Insert
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B
the ligand binding domain (recognizing all forms ofFGFR-1) are
shown in Figure 4. Three forms ofFGFR-1 were detected: the a-
form, n-form and the truncated form described above, with molec-
ular weights 135, 115 and 106 kDa respectively. The relative
amount of these isoforms varied depending on the type of breast
tissue tested. When non-malignant breast tissues were analysed,
the 106-kDa variant was the predominant form, being the darkest
band present in all 13 samples. The 115-kDa 3-form was also
detected in 7 out of the 13 normal and benign breast tissues
analysed. A faint 135-kDa band corresponding to the a-form was
seen in eight ofthese tissues. This result is consistent with the cell
line data as, in non-malignant tissue, fibroblasts, myoepithelial
cells and epithelial cells expressed the 106-kDa form of FGFR-l
whereas the 115-kDa form was expressed in epithelial cells and to
a lesser extent in myoepithelial cells. In seven out of the nine
cancers tested, the predominant variant was the 1-form, in one
the a-form predominated and in one high-grade cancer was
completely negative. The 106-kDa FGFR-1 was hardly detectable
in malignant tissues, consistent with the loss ofmyoepithelial cells
and non-expression ofthe 106-kDa FGFR-1 by breast cancercells
observed in our study ofcell lines. The small amount of 106-kDa
FGFR-1 present in breast cancers is consistent with it being
expressed only in the remaining stromal fibroblasts.
Immunohistochemistry
Although ourresults by Western blotting were very consistent, it is
possible that proteolytic degradation occurring during sample
preparation could be responsible for the smaller FGFR-I band. To
address this issue, we performed immunohistochemistry on a
range of tissues to see whether consistent results would be found
in snap-frozen sections in which no opportunity for additional
proteolytic degradation would exist. Both monoclonal antibodies
were tested for use in immunohistochemistry, however only the
monoclonal antibody against the C-terminal tail could detect
FGFR-1 in sections under a variety of different fixation methods
tested. Our Western blotting results would predict that only full-
length a- and 5-forms of FGFR-l would be detected and that
staining would be seen mainly in malignant and non-malignant
epithelial cells with reduced levels of staining in myoepithelial
cells. No staining would be expected in fibroblasts. Cryostat
sections of the 22 tissues were stained with the anti-FGFR-1
against the C-terminal epitope, and typical results are shown in
Figure 5A-D. Staining of FGFR-1 in normal breast tissue and in
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Figure 7 Determination of whether 106-kDa FGFR-1 is the a2 truncated
variant of FGFR-1. (A) Diagrammatic representation of PCR primers used in
RT-PCR analysis of the molecular form of the 106-kDa FGFR-1. TM refers to
the transmembrane domain, JM to the juxtamembrane domain, TK to the
tyrosine kinase domain, KI to the kinase insert domain and CT to the
carboxyl terminal tail. (B) Ethidium bromide-stained agarose gel of PCR
products from a reaction using primers 1 and 2 on cDNA from human breast
cell lines. Lane 1, DNA markers; lane 2, negative control; lane 3, positive
control with al FGFR-1 DNA; lane 4, positive control with a2 FGFR-1 DNA;
lane 5, cDNA from HBL-100 cells; lane 6, cDNA from MCF-1OA cells; lane 7,
cDNA from HBR-SV-161 cells; lane 8, cDNA from breastfibroblasts; lane 9,
cDNA from MDA-MB-231 cells; lane 10, cDNA from MCF-7 cells; lane 11,
cDNA from T47D cells; and lane 12, cDNA from ZR-75-1 cells
invasive breast cancer is shown together with non-immune IgG
controls. In all sections examined, the staining was predominantly
in ductal epithelial cells with similar levels of staining in malig-
nant and non-malignant epithelial cells. Reduced staining was
seen in the myoepithelial cells ofnormal ducts and no staining was
seen in stromal fibroblasts. These results are therefore consistent
with the Western blotting experiments using the same antibody
(Figure 3A).
A polyclonal antibody against amino acids 119-144 in the
extracellular region of FGFR-1 (UBI) has previously been shown
by Western blotting to be specific for FGFR-1 (New and Yeoman,
1992). This antibody was used in immunohistochemistry on the
panel ofbreast tissues and results are shown in Figure SE-H. Our
Western blotting results would predict that such an antibody
against the extracellular domain would show staining not only of
epithelial and myoepithelial cells but also of fibroblasts. This
staining pattern is seen in both malignant and non-malignant
tissues, with dark staining ofepithelial and myoepithelial cells and
paler staining ofthe stromal fibroblasts.
FGFR-1 mRNA in purified populations of breast cells
Akey issue is whetherFGFR-1 is expressed inbreast fibroblasts. It
could beargued thatthe 106-kDabandrepresentcross-reactivity of
one ofthe antibodies with a different protein. However, ifFGFR-1
mRNA is present in significant quantifies in breast fibroblasts,
FGFR-1 would be likely to be present, adding credence to the
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106-kDa band being an isoform ofFGFR-1. We used a semiquanti-
tative RT-PCR technique that has been described in detail previ-
ously (Luqmani et al, 1992) to investigate FGFR-1 mRNA
expression in purified cell populations from reduction mammo-
plasty tissue. A representative experiment is shown in Figure 6. In
all experiments, negative control lanes were entirely clear. FGFR-1
mRNA was detected in all three breast cell populations, with the
level of expression in fibroblasts being as high as that seen in
epithelial cells. Myoepithelial cells had FGFR-l-actin mRNA
ratios as high as those seen in epithelial cells, again suggesting that
the 106-kDa band detected by Western analysis is FGFR-1.
Molecular characterization of 106-kDa FGFR-1
In an attempt to characterize the 106-kDa truncated FGFR-1
further and to discover the mechanism by which it is generated, RT
products from all eight cell lines and from breast fibroblasts were
amplified by PCR using the primers shown in Figure 7A.
Although no FGFR-1 isoforms with a molecular weight of
106 kDa have been reported, it was essential to establish whether
the 106-kDa FGFR-1 corresponds to the truncated a2 receptor
(110 kDa) described by Hou et al (1991), which results from a
25-bp insertion in the second kinase domain, leading to a frame
shift and premature termination. As shown in Figure 7B, in all cell
lines and the breast fibroblasts, PCR amplification generated only
the 203-bp fragment and not the 228-bp fragment that contains the
25-bp insert. Nucleotide sequencing of this PCR product
confirmed the absence of the 25-bp insert. Therefore, no a2
FGFR-1 is expressed in breast cell lines and fibroblasts.
We conclude that a previously undescribed 106-kDa form of
FGFR-1 is expressed by epithelial, myoepithelial and fibroblasts of
the non-malignant human breast. Ithas lost a C-terminal epitope and
is likely to result from exon deletion towards the end ofthe receptor
cDNA or from a proteolytic processing event. The loss of this form
in breast cancer may have a bearing on malignant transformation.
DISCUSSION
This study describes the expression of FGFR-1 and its variant
forms in a series of normal and neoplastic breast cell lines and
tissues as well as pure populations ofepithelial and myoepithelial
cells and fibroblasts from reduction mammoplasty tissue. By
using two FGFR-1-specific monoclonal antibodies, raised against
differentepitopes ofthe receptor, we have shown differences in the
form ofFGFR-1 being expressed inmalignant compared with non-
malignant epithelial cells, as well as in different cell types.
Our results show that the FGFR-1 mRNA previously described
in breast cell lines and human breast cancers (Lehtola et al, 1992;
Luqmani et al, 1992; Luqmani et al, 1995; Penault-Llorca et al,
1995) does get translated into protein. It has previously been
shown that the predominantform ofFGFR-1 mRNA transcribed is
the 5-form with the a-form present as a minority species (Luqmani
et al, 1995; Penault-Llorca et al, 1995). Our results show that this
is also the case for the receptor proteins. In all breast cell lines
tested and in separated normal breast cells, the a-form of the
receptor was not detected, and this may indicate that, in breast
tissues, the a-form is derived from cells of a different lineage, e.g.
vascular endothelial cells or lymphocytes.
All breast cell lines tested express the 115-kDa variant of
FGFR-1 that represents the ,1 form ofthe receptor. However, the
benign cell lines express a second 106-kDa variant that is not
recognized by the antibody against the carboxyl terminus and most
likely represents a truncated form of FGFR-1. It is interesting that
this is the predominant form in myoepithelial cells and the only
form detected in fibroblasts, whereas it is undetectable in all
malignant cell lines. The 106-kDa variant is the predominant form
in benign fibroadenomata and tissues with fibrocystic disease and
is also detectable, in small amounts, in some cancers with a promi-
nent fibroblastic component. Therefore the results seen in tissue
samples mirror the situation in cell lines, with the 106-kDa FGFR-
1 being predominant in non-malignant breast samples because of
the presence of myoepithelial cells and fibroblasts. Malignant
breast tissue shows a large reduction in 106-kDa FGFR-l and,
although some of this decrease is due to the loss of myoepithelial
cells, the extent of loss suggests that the malignant epithelial cells
fail to express 106-kDa FGFR-1 in accordance with our results
studying cell lines. It is striking that all breast cancer cell lines and
tissues analysed show this phenotype.
The immunohistochemical survey of normal, benign and malig-
nant breast tissues carried out using the monoclonal antibody against
the C-terminus of FGFR-1 confirms the Western blot findings. No
staining was seen in stromal fibroblasts, consistent with the
observed expression of only the C-terminal truncated 106-kDa
FGFR-1. Myoepithelial cell staining appeared to be lighter than
epithelial cell staining, consistent with these cells expressing some
115-kDa FGFR-1 but predominantly 106-kDa FGFR-1. Immuno-
histochemistry was also useful in validating the Western blot data
with regard to potential proteolytic degradation during sample
preparation. The 106-kDa FGFR-1 is unlikely to be an artefact
produced by proteolytic degradation of the lysates, as the Western
blot experiments are entirely consistent with the immunohistochem-
ical study in which tissue samples were snap frozen immediately
after surgery, giving no chance for proteolytic degradation to occur.
Our study on the distribution of FGFR-1 mRNA in breast cell
populations is consistent with the Western data and supports the
assignment of the 106-kDa band as an isoform of FGFR-1 rather
than a different cross-reactive protein. We found FGFR-1 mRNA
in breast fibroblasts, in which the only band visible on Western
blots was at 106-kDa. We also detected higher amounts ofFGFR-
1 mRNA in myoepithelial cells than in epithelial cells, a result that
only tallies with the Western blot data if the 106-kDa band is
indeed FGFR-1.
It is not yet clear how this truncated form is generated. The
FGFR protein family is characterized by a wide variety of spliced
variants, making this an attractive possible mechanism (Jaye et al,
1992). In the case of FGFR-1, only one variant lacking the C-
terminus and having a size consistent with that observed has been
described (Hou et al, 1991). However, we have shown by RT-PCR
analysis that the 106-kDa FGFR-1 is not the truncated a2 variant
described (Hou et al, 1991). Other mechanisms leading to C-
terminal truncation have been observed in other receptors. Exon
16 deletion, leading to alteration of the carboxyl terminus of
FGFR-2 has recently been described in normal rat prostate epithe-
lial cells (Yan et al, 1993). In the case ofFGFR-1, it is possible that
deletion of one or more exons may result in the production of the
smaller 106-kDa receptor. Other possible mechanisms include
deletion of a small number of bases leading to a frame shift and
premature termination or use of alternative polyadenylation sites.
The truncation may alternatively arise as a result ofa post-transla-
tional cleavage ofthe receptor.
Seven tyrosine residues (463, 583, 585, 653, 654, 730 and 766)
in the intracellular domain of FGFR-1 have been shown to be
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autophosphorylation sites (Hou et al, 1993; Mohammadi et al,
1996). Tyrosine 766 has been characterized as the docking site for
phospholipase Cyl, with mutation of this site leading to loss of
phosphatidylinositol hydrolysis and Ca2+ flux (Mohammadi et al,
1992; Peters et al, 1992). FGFR-1 activation also leads to tyrosine
phosphorylation of SHC and activation of ERK proteins showing
that activation of p2lras is also induced (Wang et al, 1994). In
106-kDa FGFR-1, at least one of these tyrosine residues is likely
to be deleted as tyrosine 766 is relatively close to the lost epitope.
This could lead to either altered signalling properties (specifically
reduced phosphatidylinositol hydrolysis) or to an absence of
signalling ifthe kinase domain is non-functional. Ithas previously
been shown that kinase-inactive truncated FGFR-1 can inhibit
signal transduction through a dominant negative mechanism
(Ueno et al, 1992; Li et al, 1994). The signalling properties ofthe
a2 variant of FGFR-l have been studied and may be a model for
106-kDa FGFR-1 action if it acts as a dominant negative. When
a2 FGFR-1 heterodimerizes with full-length FGFR-1, tyrosine
653 is not phosphorylated; however the full length receptor is able
to phosphorylate tyrosine 766 by a cis intramolecular mechanism
(Shi et al, 1993).
It is likely that the 106-kDa truncated FGFR-1, whether gener-
ated by an alternative splicing mechanism or by proteolysis
specific to certain cell types, will have different signalling charac-
teristics to full-length FGFR-1. Its absence in breast cancer cells
may contribute to theiruncontrolled growth, lack ofdifferentiation
or metastatic behaviour. Characterization of this novel variant
form of FGFR-1 will lead to a better understanding of its precise
role and function in cellular growth and carcinogenesis.
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